^
Association details:
Biomarker:No biomarker
Cancer:Rhabdomyosarcoma
Drug:dactinomycin (Topoisomerase II inhibitor, RNA synthesis inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
COSMEGEN is indicated for the treatment of:...adult and pediatric patients with rhabdomyosarcoma, as part of a multiphase, combination chemotherapy regimen.